IsoRay Receives a Buy from Maxim Group


Maxim Group analyst Jason McCarthy maintained a Buy rating on IsoRay (NYSE MKT: ISR) today and set a price target of $2. The company’s shares closed yesterday at $0.47.

McCarthy commented:

“IsoRay reported F3Q18 with $1.57M in Cs-131 revenue, up 23% y/y, a net loss of 1.3M, and ended the period with $4.5M in cash.”

According to TipRanks.com, McCarthy is a 1-star analyst with an average return of -0.6% and a 37.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.

IsoRay has an analyst consensus of Moderate Buy, with a price target consensus of $2.

See today’s analyst top recommended stocks >>

The company has a one-year high of $0.64 and a one-year low of $0.38. Currently, IsoRay has an average volume of 114.4K.

Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ISR in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

IsoRay, Inc. is a medical technology company. Though its subsidiary IsoRay Medical, Inc., it develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts